Exploring the Role of CDO1 in Breast Cancer: Insights into Tumor Biology and Therapeutic Potential
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cysteine dioxygenase 1 (CDO1) acts as a tumor suppressor in breast cancer (BC), reducing cell viability and potentially inhibiting metastasis. Upregulation of CDO1 shows promise as a prognostic biomarker for BC.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Breast cancer (BC) is a heterogeneous disease requiring novel biomarkers and therapeutic targets.
- The role of the cysteine dioxygenase 1 (CDO1) gene in BC progression and patient outcomes needs investigation.
Purpose Of The Study
- To investigate the function of CDO1 in breast cancer.
- To assess CDO1's potential as a prognostic biomarker.
Main Methods
- Stable transfection of CDO1 in MDA-MB231 triple-negative BC cells.
- Gene expression profiling using microarray analysis.
- Correlation analysis in clinical BC samples and functional assays.
Main Results
- CDO1 upregulation induced tumor suppressor genes (DEFB1, HOPX, FRMD3).
- CDO1 expression correlated with SLC1A7 and KITLG in clinical samples.
- CDO1 increased apoptosis, reduced cell viability, and altered oncogenic pathways, suggesting reduced metastatic potential.
Conclusions
- CDO1 significantly modulates BC behavior.
- CDO1 shows potential as a prognostic biomarker for breast cancer.
- Further research is needed to explore CDO1's mechanisms and therapeutic potential in triple-negative BC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...